Non-hodgkin Lymphoma

Overview

Non-Hodgkin lymphoma (NHL) is a type of cancer that originates in the lymphatic system. It is a complex disease with many different subtypes, each characterized by specific cellular and genetic features. NHL can affect people of all ages, although it tends to occur more frequently in individuals over the age of 60. The lymphatic system is an essential component of the immune system, responsible for protecting the body against infections and other foreign substances. Lymphocytes are a type of white blood cell that plays a crucial role in the lymphatic system. In NHL patients, these lymphocytes grow and multiply abnormally, forming tumors in various parts of the body. Symptoms of NHL can vary widely, depending on the location and stage of the tumors. Common symptoms include swollen lymph nodes, fever, weight loss, night sweats, and fatigue. NHL can be diagnosed through a variety of tests, including blood tests, biopsies, and imaging studies. Treatment options for NHL depend on the subtype and stage of the disease, as well as the patient's age and overall health. In many cases, treatment involves a combination of chemotherapy, radiation therapy, and immunotherapy. Clinical trials of novel therapies, such as CAR T-cell therapy and targeted therapies, are also ongoing. Advances in understanding the biology of NHL have led to the development of increasingly sophisticated treatments that can improve outcomes for patients. Hematology and oncology researchers continue to investigate new approaches to diagnosis, treatment, and prevention of NHL, with the hope of ultimately eradicating this disease.

Research published in this journal

12 peer-reviewed articles, ranked by relevance. Each links to its DOI.

How this research is being cited

The 12 articles above have been cited 31 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.

• Exploring the Potential of Receptor Silencing in the Tumor Microenvironment by RNA Interference
  2026 · Biomolecules
• Effect of vitamin D status on a disintegrin-like and metalloprotease with thrombospondin type 1 motif 13 (ADAMTS13) and interleukin 6 in patients with acute myeloid leukaemia
  Dina Ashraf Abdelhady et al. · 2025 · European Journal of Medical Research
• Effect of vitamin D status on a disintegrin-like and metalloprotease with thrombospondin type 1 motif 13 (ADAMTS13) and interleukin 6 in patients with acute myeloid leukaemia
  2025 · European journal of medical research
• Analysis of the efficacy and prognostic factors of gemcitabine combined with oxaliplatin in non‑Hodgkin lymphoma
  2025 · Oncology Letters
• A real-world pharmacovigilance study using disproportionality analysis of United States Food and Drug Administration Adverse Event Reporting System events for vinca alkaloids: comparing vinorelbine and Vincristine
  2024 · Expert Opinion on Drug Safety
• A real-world pharmacovigilance study using disproportionality analysis of united states food and drug administration adverse event reporting system events for vinca alkaloids: comparing vinorelbine and Vincristine
  2024 · Expert Opinion on Drug Safety
• The Prognostic Value of Pretreatment Serum LDH at Diagnosis in Patients with Hodgkin Lymphoma
  2023 · International Journal of Medical Science
• A comprehensive update of siRNA delivery design strategies for targeted and effective gene silencing in gene therapy and other applications
  2023 · Expert Opinion on Drug Discovery

A sample of recent works citing this journal's research on Non-hodgkin Lymphoma, linking to each citing work.

This page summarises published research for orientation; it is not medical or professional advice.

Related topics